Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07566130 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT07566130 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 93 participants.
The verdict
NCT07566130, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
The objectives for this 2 Part study are to assess the safety, tolerability, and pharmacokinetics following single ascending oral doses of nacresertib in healthy adult participants (Part 1) and to assess the safety, tolerability, and pharmacokinetics following multiple ascending oral doses in healthy adult participants (Part 2).
Interventions
- DRUG Placebo
- DRUG nacresertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2025-04-18 |
| Est. Completion | 2026-05-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07566130
The ClinicalTrials.gov registry entry for NCT07566130 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07566130 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07566130 about?
NCT07566130 is a clinical study titled "A Study to Assess Adverse Events, Tolerability and How Single and Ascending Oral Doses of Nacresertib Move Through the Body In Healthy Adult Participants". The objectives for this 2 Part study are to assess the safety, tolerability, and pharmacokinetics following single ascending oral doses of nacresertib in healthy adult participants (Part 1) and to assess the safety, tolerability, and pharmacokinetics following multiple ascending oral doses in health...
What is the current status of trial NCT07566130?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2025-04-18. Estimated completion is 2026-05-07.
What interventions are being tested in trial NCT07566130?
The interventions under investigation include: Placebo (DRUG), nacresertib (DRUG).
Who is sponsoring clinical trial NCT07566130?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.